PTC Therapeutics, Inc.
$4.13B- Market cap
- $5.78B
- Debt
- +$286.63M
- Cash
- −$1.95B
Capital structure 95% equity / 5% debt · EV / Revenue 2.38x · EV / EBITDA 5.50x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 ·
Decision snapshot: PTCT stock price at discount vs VEEV $69.30 current versus $393.42 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VEEV's multiple
Implied fair value · at PTCT's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: PTCT FY 2025 (ended Dec 31, 2025) · VEEV FY 2026 (ended Jan 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 95% equity / 5% debt · EV / Revenue 2.38x · EV / EBITDA 5.50x
Capital structure 100% equity / 0% debt · EV / Revenue 13.53x · EV / EBITDA 35.40x
VEEV carries the larger enterprise value at $43.23B against $4.13B; PTCT trades on the lower EV / Revenue multiple (2.38x vs 13.53x); PTCT on the lower EV / EBITDA (5.50x vs 35.40x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PTC Therapeutics, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Veeva Systems Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-1.40x
0.02x
Net debt / EBITDA
Leverage against operating earnings
-2.21x
-1.08x
Cash and equivalents
Liquid reserves on the balance sheet
$1.95B
$1.42B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
VERTEX PHARMACEUTICALS INC / MA
PTCT vs VRTX
Sarepta Therapeutics, Inc.
PTCT vs SRPT
BIOMARIN PHARMACEUTICAL INC
PTCT vs BMRN
ALNYLAM PHARMACEUTICALS, INC.
PTCT vs ALNY
Salesforce, Inc.
PTCT vs CRM
Adobe Inc.
PTCT vs ADBE
Microsoft Corporation
PTCT vs MSFT
Oracle Corporation
PTCT vs ORCL
$286.63M
$108.32M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.